TOP
STORY

Researchers showed that the immunosuppression activity of programmed death ligand-1 (PD-L1) is stringently modulated by ubiquitination and N-glycosylation. They showed that glycogen synthase kinase 3β interacts with PD-L1 and induces phosphorylation-dependent proteasome degradation of PD-L1 by β-TrCP. [Nat Commun]
Full Article

The authors demonstrated that Bach2 associates with Batf and binds to the regulatory regions of the Th2 cytokine gene loci. The Bach2–Batf complex antagonizes the recruitment of the Batf–Irf4 complex to AP-1 motifs and suppresses Th2 cytokine production. [Nat Commun]
Full Article

Scientists investigated the mechanism of action of L-pampo, a proprietary adjuvant composed of Toll-like receptor (TLR)1/2 and TLR3 ligands. L-pampo dramatically increased humoral immune responses against the tested target antigens, which was correlated with an increase in follicular helper T cells and the maintenance of antigen-specific CD4+ T cells. [Sci Rep]
Full Article

The authors found that the peripheral Foxp3+ regulatory T cells (pTreg) T cell receptor did not inevitably predispose T cells to become pTreg but instead allowed for differentiation of noninflammatory CD4+CD8αα+ intraepithelial lymphocytes in the small intestine. [Sci Immunol]
Abstract

The author covers the mucosal immune system of the gastrointestinal tract and the immunological mechanisms underlying IgE-mediated food allergy, as well as introduces cells recently identified to have a role in the hypersensitivity reaction to food allergens. [J Allergy Clin Immunol]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the immune regulation research field.

Sunesis Pharmaceuticals, Inc. announced that a poster detailing preliminary results from the company’s Phase IA study in healthy volunteers evaluating oral non-covalent BTK-inhibitor SNS-062 will be presented. [Press release from Sunesis Pharmaceuticals, Inc. discussing research to be presented at the European School of Haematology’s 2nd International Conference on New Concepts in B-Cell Malignancies]
Press Release

Amgen and Boehringer Ingelheim announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836909, a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen, a potential target for multiple myeloma. BI 836909 is currently in Phase I studies. [Amgen Inc.]
Press Release

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application for BLINCYTO® to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. [Amgen Inc.]
Press Release

On a Friday in March 2013, a researcher working in the lab of a prominent pulmonary scientist at Duke University in Durham, North Carolina, was arrested on charges of embezzlement. The researcher, biologist Erin Potts-Kant, later pled guilty to siphoning more than $25,000 from the Duke University Health System, buying merchandise from Amazon, Walmart, and Target—even faking receipts to legitimize her purchases. [ScienceInsider]
Editorial

The UK government and the Crick’s other funders have gambled £700 million (US$927 million) on the institute, in the hope that it will attract some of world’s brightest young biomedical researchers to Britain and catalyze a boom in the UK life-sciences economy. [Nature News]
Editorial